Exelixis sets 2025 guidance in line with estimates

More on Exelixis

• Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
• Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
• Seeking Alpha | January 13, 2025

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

ALAMEDA, Calif., January 12, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as multiple data readouts for zanzalintinib and across its diversified pipeline of small molecules and biotherapeutics w

Yahoo | January 12, 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.

Yahoo | January 10, 2025

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif., January 09, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration b

Yahoo | January 9, 2025

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

ALAMEDA, Calif., January 06, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT.

Yahoo | January 6, 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.

Yahoo | January 6, 2025

Exelixis price target raised to $38 from $34 at RBC Capital

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into the firm’s valuation. The firm sees the nearest opportunity in metastatic colorectal cancer and incorporates the valuation in mCRC into its model at a 40% odds of success, the analys

Yahoo | December 31, 2024

High Growth Tech Stocks to Watch in December 2024

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving industry landscape.

Yahoo | December 30, 2024

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | December 27, 2024

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

EXEL vs. INCY: Which Stock Is the Better Value Option?

Yahoo | December 25, 2024